Polish med-tech firm Neuromedical, which raised $1.3 million (PLN 5.5 million), has developed the Vguard device, shown in studies to improve cognitive function in patients with Alzheimer’s disease, and plans to make it available in Poland in 2026, as Vestbee was informed.
- Neuromedical develops therapies for Alzheimer’s disease. Its main technology, the Vguard device, uses non-invasive transcutaneous vagus nerve stimulation (tVNS) during sleep to support memory consolidation and slow cognitive decline in patients with mild cognitive impairment and early-stage Alzheimer’s.
- Designed for at-home use, the system operates under a hardware-as-a-service model, allowing treatment data to be transmitted directly to supervising physicians.
- Neuromedical’s approach has been validated in scientific studies and clinical experiments, holds CE/MDR certification for use in Europe, and the company is conducting multi-center clinical trials with plans to expand into other European markets while pursuing FDA approval.
Details of the deal
- The investment was led by Hard2beat, a Polish VC fund backing early-stage deep tech startups with capital and strategic support.
- The round also saw support from angel investors including Piotr and Tomasz Karwatka, Anna Lankauf, Paweł Lisowski, and Vladyslav Muzhylivskyi.
“Our decision to make a follow-on investment was a direct result of the company delivering on the milestones set at the outset — in particular, obtaining CE/MDR certification, which opens the door to commercial sales in Europe. I’m pleased that experienced angel investors joined the round. This signals the maturation of Poland’s angel investment market and growing capital availability for bold, high-impact projects capable of helping large numbers of people," claims Konrad Trzyna, Managing Partner at Hard2beat.
- With the fresh capital, the firm aims to run multi-center clinical trials and prepare the Vguard device for commercialization, starting with a limited rollout in Poland and expanding to other European markets while pursuing US. FDA clearance.
